Celgene sales and marketing update

The U.K.’s NICE issued final guidance recommending against Abraxane nab-paclitaxel from Celgene to treat pancreatic cancer in combination with gemcitabine. The agency said the cost of the drug is not justified by its “limited benefits compared to current treatments.” ...